adenosine + amiodarone + digoxin + flecainide + procainamide + propranolol

This therapeutic regimen consists of a collection of antiarrhythmic agents evaluated in a clinical audit at Assiut University Children Hospital for the management of supraventricular tachycardia (SVT) in pediatric patients. The regimen includes **adenosine** (an AV nodal blocking agent), **propranolol** (a non-selective beta-blocker), **flecainide** (a Class Ic antiarrhythmic), **amiodarone** (a Class III antiarrhythmic with multi-channel blocking properties), **digoxin** (a cardiac glycoside), and **procainamide** (a Class Ia antiarrhythmic). These drugs are utilized either sequentially or in combination to terminate acute SVT episodes or provide long-term rhythm control, adhering to international guidelines for pediatric cardiology. The audit specifically assesses the efficacy and safety of these established pharmaceuticals in a real-world clinical setting within a pediatric population.

Other names

adenosine, Propranolol, flecainide, amiodarone, propranolol, digoxin and procainamide